![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 30, 2013 1:39:57 PM
and the rest of the Scientific Advisors ... for LUNGevity -- happen to see David Carbone in there
Denise R. Aberle, MD
David Geffen School of Medicine at UCLA
Professor and Vice Chair of Research, Radiology
Nasser Altorki, MB, BCh
NewYork-Presbyterian/Weill Cornell Medical Center
Professor of Cardiothoracic Surgery
Chief, Division of Thoracic Surgery
Philip D. Bonomi, MD
Rush University Medical Center
Alice Pirie Wirtz Professor of Medical Oncology
Director, Division of Hematology-Oncology
David Carbone, MD, PhD
The Ohio State University
Professor, Division of Medical Oncology
Barbara J. Bonner Chair in Lung Cancer Research
Director of the Thoracic Oncology Center
Martin "Mac" Cheever, MD
Fred Hutchinson Cancer Research Center
Director, Cancer Immunotherapy Trials Network
Steven M. Dubinett, MD
David Geffen School of Medicine at UCLA
Chief, Division of Pulmonary and Critical Care Medicine
Senior Associate Dean for Translational Research
Associate Vice Chancellor for Research
Director, Clinical and Translational Science Institute (CTSI)
John V. Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center
Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
James Jett, MD
National Jewish Health
Professor of Medicine
Robert L. Keith, MD
University of Colorado, Denver
Professor of Medicine and Cancer Biology
Denver VAMC
Associate Chief of Staff - Research
J. Jack Lee, PhD, DDS
The University of Texas MD Anderson Cancer Center
Professor of Biostatistics
Kenedy Foundation Chair in Cancer Research
Scott Lippman, MD
University of California, San Diego
Director, Moores Cancer Center
Chugai Pharmaceutical Chair
Professor of Medicine
Pierre Massion, MD
Vanderbilt-Ingram Cancer Center
Professor of Medicine and Cancer Biology
Director, Thoracic Program
Charles Rudin, MD, PhD
Memorial Sloan-Kettering Cancer Center
Chief, Thoracic Oncology Service
Lawrence H. Schwartz, MD
Columbia University Medical Center
James Picker Professor and Chairman, Department of Radiology
NewYork Presbyterian Hospital/Columbia University Medical Center
Radiologist-in-Chief
Lecia V. Sequist, MD, MPH
Harvard Medical School
Associate Professor of Medicine
Massachusetts General Hospital Cancer Center - Center for Thoracic Cancer
Attending Oncologist
Steven J. Skates, PhD
Harvard Medical School and Massachusetts General Hospital
Associate Professor
Avrum Spira, MD, MSci
Boston University
Professor of Medicine, Pathology and Bioinformatics
Alexander Graham Bell Professor in Healthcare Entrepreneurship
Chief, Section of Computational Biomedicine
Margaret R. Spitz, MD, MPH
Baylor College of Medicine
Professor, Dan L. Duncan Cancer Center
http://events.lungevity.org/site/PageServer?pagename=v2_AboutUs_ScientificAdvisoryBoard
---------------------------------------------------------------
.... for those that didn't know... David Carbone is with Bristol Myers Squibb, maybe he is trying to save the deal... tell them (BMS) to open that vault all the way : ) - for confirmation you can see David Carbones name at the very end of this site-- names are highlighted ( no Dr. Robert Schwartz in there though : )
http://www.gotoper.com/conferences/ilc/meetings/14th-international-lung-cancer-congress
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM